Mineralys to present data showing lorundrostat modulates heart failure biomarkers
MLYS•Mineralys Therapeutics will present late-breaking post hoc proteomic data at ENDO 2026 showing lorundrostat modulates heart failure risk biomarkers in uncontrolled hypertension participants from its Phase 3 Launch-HTN and Phase 2 Advance-HTN trials. The poster (SUN-257) is scheduled for June 14 in the Cardiovascular Endocrinology session in Chicago.
1. ENDO 2026 Presentation Details
Mineralys will feature a late-breaking poster (Abstract SUN-257) on June 14 from 9:00 AM to 4:00 PM CT in the Cardiovascular Endocrinology: Hormone Systems and Blood Vessel Health II session at McCormick Place West in Chicago.
2. Post Hoc Proteomic Analysis
The presentation covers a proteomic analysis of circulating heart failure risk biomarkers in participants from the Launch-HTN and Advance-HTN trials, demonstrating that lorundrostat treatment alters key protein markers associated with cardiovascular risk in uncontrolled hypertension.
3. Trial Design Background
Launch-HTN was a global Phase 3, double-blind trial randomizing uncontrolled hypertension patients on two to five medications to lorundrostat 50 mg (with optional increase to 100 mg) or placebo for six weeks. Advance-HTN was a Phase 2 trial evaluating lorundrostat added to a standardized regimen over 12 weeks with similar dosing cohorts versus placebo.
4. Strategic Implications
Modulation of heart failure biomarkers could bolster lorundrostat’s therapeutic profile beyond blood pressure reduction, potentially strengthening its NDA submission ahead of FDA review and enhancing differentiation in the uncontrolled and resistant hypertension markets.
